Sections

Sections Central Serous Chorioretinopathy
Overview
Presentation
- History
- Physical
- Causes
- Show All
DDx
Workup
Treatment
Medication
Media Gallery
References

Workup

Laboratory Studies

Laboratory tests, in general, are not helpful in the diagnosis of central serous chorioretinopathy (CSCR), although a recent case report identified an elevated level of plasminogen activator inhibitor 1 in the serum of patients with CSCR.

Imaging Studies

Optical coherence tomography (OCT) reveals many aspects of the pathophysiology of CSCR, ranging from subretinal fluid, pigment epithelial detachments, and retinal atrophy following chronic disease. OCT is especially helpful in identifying subtle, even subclinical, neurosensory macular detachments. Spaide correlated lipofuscinoid deposition of material in CSCR that might mimic vitelliform lesions in pattern dystrophies.^[47]OCT showed accumulation of this material on the outer surface of the retina in neurosensory detachments.

A 45-year-old man presented with micropsia and blurry vision OS. His visual acuity was 20/15 OD and 20/30 OS. The OCT shows subretinal fluid localized under the foveal center. Six weeks later, the subretinal fluid had resolved and his vision had recovered to 20/15 OU.

View Media Gallery

FA of classic CSCR shows one or more focal leaks at the level of the RPE. The classic "smokestack" appearance of the fluorescein leak is seen only in 10-15% of cases. FA of diffuse retinal pigment epitheliopathy demonstrates focal granular hyperfluorescence corresponding to window defects and blockage caused by RPE atrophy and clumping with one or more areas of subtle continued leakage.^[28]

Fluorescein angiography in the early recirculation phase of a patient with a localized neurosensory detachment in the macula from central serous chorioretinopathy. Note the focal hyperfluorescence.

View Media Gallery

Fluorescein angiography in the late recirculation phase of the same patient as in the image above. Note the distribution of leakage of fluorescein dye within the neurosensory detachment.

View Media Gallery

ICG angiography has shown hypofluorescent areas early in the angiogram followed by late hyperfluorescence and leakage in choroidal vasculature. Often, multiple areas of leakage are seen on ICG angiography that are not evident clinically or on FA. According to some researchers, characteristic mid phase findings on ICG angiography allow differentiation from occult choroidal neovascularization in older individuals. Multiple patches of hyperfluorescence presumably are due to choroidal hyperpermeability, which, in later phases, results in silhouetting or negative staining of larger choroidal vessels.

Newer technology to evaluate the retina is available. Ooto et al showed that adaptive optics scanning laser ophthalmoscopy is useful in evaluating cone abnormalities associated with visual acuity loss in eyes with CSCR.^[48]

Other Tests

Multifocal electroretinography has been used to identify focal regions of decreased retinal function, even in asymptomatic or clinically inactive eyes. Chappelow and Marmor first described the persistently reduced focal electrical responses on multifocal electroretinography in eyes with resolved CSCR.^[49]Furthermore, investigators, including Lai et al, are using multifocal electroretinography as a means of assessing the efficacy and safety of new treatment modalities for CSCR.^[50]

Microperimetry (using the Nidek MP-1 microperimeter) has also shown that, despite clinical resolution of CSCR, there is lower retinal sensitivity in the macula even once visual acuity returned to 20/20. Ojima et al showed that areas of reduced sensitivity were typically focal and localized to clinically apparent regions of irregular RPE. Fixation studies showed stability of central fixation.^{[51, 52]}

Treatment & Management

Okushiba U, Takeda M. [Study of choroidal vascular lesions in central serous chorioretinopathy using indocyanine green angiography]. Nihon Ganka Gakkai Zasshi. 1997 Jan. 101(1):74-82. [QxMD MEDLINE Link].
Iijima H, Iida T, Murayama K, Imai M, Gohdo T. Plasminogen activator inhibitor 1 in central serous chorioretinopathy. Am J Ophthalmol. 1999 Apr. 127(4):477-8. [QxMD MEDLINE Link].
Marmor MF, Tan F. Central serous chorioretinopathy: bilateral multifocal electroretinographic abnormalities. Arch Ophthalmol. 1999 Feb. 117(2):184-8. [QxMD MEDLINE Link].
Carvalho-Recchia CA, Yannuzzi LA, Negrao S, et al. Corticosteroids and central serous chorioretinopathy. Ophthalmology. 2002 Oct. 109(10):1834-7. [QxMD MEDLINE Link].
Daruich A, Matet A, Dirani A, Bousquet E, Zhao M, Farman N, et al. Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis. Prog Retin Eye Res. 2015 Sep. 48:82-118. [QxMD MEDLINE Link].
Leveque TK, Yu L, Musch DC, Chervin RD, Zacks DN. Central serous chorioretinopathy and risk for obstructive sleep apnea. Sleep Breath. 2007 Dec. 11(4):253-7. [QxMD MEDLINE Link].
Tewari HK, Gadia R, Kumar D, Venkatesh P, Garg SP. Sympathetic-parasympathetic activity and reactivity in central serous chorioretinopathy: a case-control study. Invest Ophthalmol Vis Sci. 2006 Aug. 47(8):3474-8. [QxMD MEDLINE Link].
Cotticelli L, Borrelli M, D'Alessio AC, et al. Central serous chorioretinopathy and Helicobacter pylori. Eur J Ophthalmol. 2006 Mar-Apr. 16(2):274-8. [QxMD MEDLINE Link].
Casella AM, Berbel RF, Bressanim GL, Malaguido MR, Cardillo JA. Helicobacter pylori as a potential target for the treatment of central serous chorioretinopathy. Clinics (Sao Paulo). 2012 Sep. 67(9):1047-52. [QxMD MEDLINE Link].
Liew G, Quin G, Gillies M, Fraser-Bell S. Central serous chorioretinopathy: a review of epidemiology and pathophysiology. Clin Experiment Ophthalmol. 2012 Jul 12. [QxMD MEDLINE Link].
Zavoloka O, Bezditko P, Lahorzhevska I, Zubkova D, Ilyina Y. Clinical efficiency of Helicobacter pylori eradication in the treatment of patients with acute central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2016 Sep. 254 (9):1737-42. [QxMD MEDLINE Link].
Can ME, Kaplan FE, Uzel MM, Kiziltoprak H, Ergun MC, Koc M, et al. The association of Helicobacter pylori with choroidal and retinal nerve fiber layer thickness. Int Ophthalmol. 2018 Oct. 38 (5):1915-1922. [QxMD MEDLINE Link].
Horozoglu F, Sever O, Celik E, Mete R, Sahin E. Choroidal Thickness of Helicobacter-Positive Patients without Central Serous Chorioretinopathy. Curr Eye Res. 2018 Feb. 43 (2):262-265. [QxMD MEDLINE Link].
Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980-2002. Ophthalmology. 2008 Jan. 115(1):169-73. [QxMD MEDLINE Link].
Li Y, You QS, Wei WB, Xu J, Chen CX, Wang YX, et al. Prevalence and associations of central serous chorioretinopathy in elderly Chinese. The Beijing Eye Study 2011. Acta Ophthalmol. 2016 Jun. 94 (4):386-90. [QxMD MEDLINE Link].
Gomolin JE. Choroidal neovascularization and central serous chorioretinopathy. Can J Ophthalmol. 1989 Feb. 24(1):20-3. [QxMD MEDLINE Link].
Matsunaga H, Nangoh K, Uyama M, Nanbu H, Fujiseki Y, Takahashi K. [Occurrence of choroidal neovascularization following photocoagulation treatment for central serous retinopathy]. Nihon Ganka Gakkai Zasshi. 1995 Apr. 99(4):460-8. [QxMD MEDLINE Link].
Otsuka S, Ohba N, Nakao K. A long-term follow-up study of severe variant of central serous chorioretinopathy. Retina. 2002 Feb. 22(1):25-32. [QxMD MEDLINE Link].
Tsai DC, Huang CC, Chen SJ, et al. Central serous chorioretinopathy and risk of ischaemic stroke: a population-based cohort study. Br J Ophthalmol. 2012 Dec. 96(12):1484-8. [QxMD MEDLINE Link].
Chang YS, Chang C, Weng SF, Wang JJ, Jan RL. RISK OF RHEGMATOGENOUS RETINAL DETACHMENT WITH CENTRAL SEROUS CHORIORETINOPATHY. Retina. 2016 Aug. 36 (8):1446-53. [QxMD MEDLINE Link].
Chang YS, Chang C, Weng SF, Wang JJ, Jan RL. RISK OF RETINAL VEIN OCCLUSION WITH CENTRAL SEROUS CHORIORETINOPATHY. Retina. 2016 Apr. 36 (4):798-804. [QxMD MEDLINE Link].
Mehta PH, Chhablani J, Wang J, Meyerle CB. Central Serous Chorioretinopathy in African Americans at Wilmer Eye Institute. J Natl Med Assoc. 2018 Jun. 110 (3):297-302. [QxMD MEDLINE Link].
Spaide RF, Campeas L, Haas A, et al. Central serous chorioretinopathy in younger and older adults. Ophthalmology. 1996 Dec. 103(12):2070-9; discussion 2079-80. [QxMD MEDLINE Link].
Polak BC, Baarsma GS, Snyers B. Diffuse retinal pigment epitheliopathy complicating systemic corticosteroid treatment. Br J Ophthalmol. 1995 Oct. 79(10):922-5. [QxMD MEDLINE Link]. [Full Text].
Folk JC, Thompson HS, Han DP, Brown CK. Visual function abnormalities in central serous retinopathy. Arch Ophthalmol. 1984 Sep. 102(9):1299-302. [QxMD MEDLINE Link].
Castro-Correia J, Coutinho MF, Rosas V, Maia J. Long-term follow-up of central serous retinopathy in 150 patients. Doc Ophthalmol. 1992. 81(4):379-86. [QxMD MEDLINE Link].
Yap EY, Robertson DM. The long-term outcome of central serous chorioretinopathy. Arch Ophthalmol. 1996 Jun. 114(6):689-92. [QxMD MEDLINE Link].
Gass JDM. Stereoscopic Atlas of Macular Disease. 4th ed. 1997. 52-70.
Gass JD. Central serous chorioretinopathy and white subretinal exudation during pregnancy. Arch Ophthalmol. 1991 May. 109(5):677-81. [QxMD MEDLINE Link].
Piccolino FC, Borgia L. Central serous chorioretinopathy and indocyanine green angiography. Retina. 1994. 14(3):231-42. [QxMD MEDLINE Link].
Yannuzzi LA. Type-A behavior and central serous chorioretinopathy. Retina. 1987 Summer. 7(2):111-31. [QxMD MEDLINE Link].
Jampol LM, Weinreb R, Yannuzzi L. Involvement of corticosteroids and catecholamines in the pathogenesis of central serous chorioretinopathy: a rationale for new treatment strategies. Ophthalmology. 2002 Oct. 109(10):1765-6. [QxMD MEDLINE Link].
Allibhai ZA, Gale JS, Sheidow TS. Central serous chorioretinopathy in a patient taking sildenafil citrate. Ophthalmic Surg Lasers Imaging. 2004 Mar-Apr. 35(2):165-7. [QxMD MEDLINE Link].
Fraunfelder FW, Franufelder FT. Central serous chorioretinopathy associated with sildenafil. Retina. 2008. 28:606-9.
Daruich A, Matet A, Dirani A, Bousquet E, Zhao M, Farman N, et al. Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis. Prog Retin Eye Res. 2015 Sep. 48:82-118. [QxMD MEDLINE Link].
Breukink MB, Schellevis RL, Boon CJ, Fauser S, Hoyng CB, den Hollander AI, et al. Genomic Copy Number Variations of the Complement Component C4B Gene Are Associated With Chronic Central Serous Chorioretinopathy. Invest Ophthalmol Vis Sci. 56:5608-13. [QxMD MEDLINE Link].
Moschos MM, Gazouli M, Gatzioufas Z, Brouzas D, Nomikarios N, Sivaprasad S, et al. PREVALENCE OF THE COMPLEMENT FACTOR H AND GSTM1 GENES POLYMORPHISMS IN PATIENTS WITH CENTRAL SEROUS CHORIORETINOPATHY. Retina. 2015 Aug 19. [QxMD MEDLINE Link].
Cunningham ET Jr, Alfred PR, Irvine AR. Central serous chorioretinopathy in patients with systemic lupus erythematosus. Ophthalmology. 1996 Dec. 103(12):2081-90. [QxMD MEDLINE Link].
Bouzas EA, Scott MH, Mastorakos G, Chrousos GP, Kaiser-Kupfer MI. Central serous chorioretinopathy in endogenous hypercortisolism. Arch Ophthalmol. 1993 Sep. 111(9):1229-33. [QxMD MEDLINE Link].
Mansuetta CC, Mason JO 3rd, Swanner J, et al. An association between central serous chorioretinopathy and gastroesophageal reflux disease. Am J Ophthalmol. 2004 Jun. 137(6):1096-100. [QxMD MEDLINE Link].
Tittl MK, Spaide RF, Wong D, et al. Systemic findings associated with central serous chorioretinopathy. Am J Ophthalmol. 1999 Jul. 128(1):63-8. [QxMD MEDLINE Link].
Haimovici R, Koh S, Gagnon DR, Lehrfeld T, Wellik S. Risk factors for central serous chorioretinopathy: a case-control study. Ophthalmology. 2004 Feb. 111(2):244-9. [QxMD MEDLINE Link].
Sahoo NK, Singh SR, Rajendran A, Shukla D, Chhablani J. Masqueraders of central serous chorioretinopathy. Surv Ophthalmol. 2019 Jan - Feb. 64 (1):30-44. [QxMD MEDLINE Link].
Alfonso-Muñoz EA, Dolz-Marco R. Bestrophinopathy Mimicking Central Serous Chorioretinopathy. Ophthalmol Retina. 2018 Aug. 2 (8):857. [QxMD MEDLINE Link].
Kumawat D, Anjum S, Sahay P, Chawla R. Central serous chorioretinopathy in a patient of juxtapapillary excavation misdiagnosed as optic disc pit maculopathy. BMJ Case Rep. 2018 Nov 1. 2018:[QxMD MEDLINE Link].
Ozkaya A, Garip R, Nur Tarakcioglu H, Alkin Z, Taskapili M. Clinical and imaging findings of pattern dystrophy subtypes; Diagnostic errors and unnecessary treatment in clinical practice. J Fr Ophtalmol. 2018 Jan. 41 (1):21-29. [QxMD MEDLINE Link].
Spaide RF. Deposition of yellow submacular material in central serous chorioretinopathy resembling adult-onset foveomacular vitelliform dystrophy. Retina. 2004 Apr. 24(2):301-4. [QxMD MEDLINE Link].
Ooto S, Hangai M, Sakamoto A, et al. High-resolution imaging of resolved central serous chorioretinopathy using adaptive optics scanning laser ophthalmoscopy. Ophthalmology. 2010 Sep. 117(9):1800-9, 1809.e1-2. [QxMD MEDLINE Link].
Chappelow AV, Marmor MF. Multifocal electroretinogram abnormalities persist following resolution of central serous chorioretinopathy. Arch Ophthalmol. 2000 Sep. 118(9):1211-5. [QxMD MEDLINE Link].
Lai TY, Chan WM, Li H, Lai RY, Liu DT, Lam DS. Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study. Br J Ophthalmol. 2006 Jul. 90(7):869-74. [QxMD MEDLINE Link]. [Full Text].
Ozdemir H, Karacorlu SA, Senturk F, Karacorlu M, Uysal O. Assessment of macular function by microperimetry in unilateral resolved central serous chorioretinopathy. Eye (Lond). 2008 Feb. 22(2):204-8. [QxMD MEDLINE Link].
Ojima Y, Tsujikawa A, Hangai M, et al. Retinal sensitivity measured with microperimeter 1 after resolution of central serous chorioretinopathy. Am J Ophthalmol. 2008. 146:77-84.
Tatham A, Macfarlane A. The use of propranolol to treat central serous chorioretinopathy: an evaluation by serial OCT. J Ocul Pharmacol Ther. 2006 Apr. 22(2):145-9. [QxMD MEDLINE Link].
Nielsen JS, Weinreb RN, Yannuzzi L, Jampol LM. Mifepristone treatment of chronic central serous chorioretinopathy. Retina. 2007 Jan. 27(1):119-22. [QxMD MEDLINE Link].
Forooghian F, Meleth AD, Cukras C, Chew EY, Wong WT, Meyerle CB. Finasteride for chronic central serous chorioretinopathy. Retina. 2011 Apr. 31(4):766-71. [QxMD MEDLINE Link]. [Full Text].
Steinle NC, Gupta N, Yuan A, Singh RP. Oral rifampin utilisation for the treatment of chronic multifocal central serous retinopathy. Br J Ophthalmol. 2012 Jan. 96(1):10-3. [QxMD MEDLINE Link].
Shulman S, Goldenberg D, Schwartz R, Habot-Wilner Z, Barak A, Ehrlich N, et al. Oral Rifampin treatment for longstanding chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2015 Mar 21. [QxMD MEDLINE Link].
Nelson J, Saggau DD, Nielsen JS. Rifampin induced hepatotoxicity during treatment for chronic central serous chorioretinopathy. Retin Cases Brief Rep. 2014 Winter. 8 (1):70-2. [QxMD MEDLINE Link].
Kurup SK, Oliver A, Emanuelli A, Hau V, Callanan D. Low-dose methotrexate for the treatment of chronic central serous chorioretinopathy: a retrospective analysis. Retina. 2012 Nov-Dec. 32(10):2096-101. [QxMD MEDLINE Link].
Chin EK, Almeida DR, Roybal CN, Niles PI, Gehrs KM, Sohn EH, et al. Oral mineralocorticoid antagonists for recalcitrant central serous chorioretinopathy. Clin Ophthalmol. 2015. 9:1449-56. [QxMD MEDLINE Link].
Bousquet E, Beydoun T, Rothschild PR, Bergin C, Zhao M, Batista R, et al. SPIRONOLACTONE FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY: A Randomized Controlled Crossover Study. Retina. 2015 May 26. [QxMD MEDLINE Link].
Salz DA, Pitcher JD 3rd, Hsu J, Regillo CD, Fineman MS, Elliott KS, et al. Oral eplerenone for treatment of chronic central serous chorioretinopathy: a case series. Ophthalmic Surg Lasers Imaging Retina. 2015 Apr. 46 (4):439-44. [QxMD MEDLINE Link].
Huang WC, Chen WL, Tsai YY, Chiang CC, Lin JM. Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy. Eye (Lond). 2009 Feb. 23(2):488-9. [QxMD MEDLINE Link].
Torres-Soriano ME, Garcia-Aguirre G, Kon-Jara V, et al. A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (case reports). Graefes Arch Clin Exp Ophthalmol. 2008 Sep. 246(9):1235-9. [QxMD MEDLINE Link].
Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. Am J Ophthalmol. 2007 Jun. 143(6):977-983. [QxMD MEDLINE Link].
Tekin K, Sekeroglu MA, Cankaya AB, Teke MY, Doguizi S, Yilmazbas P. Intravitreal Bevacizumab and Ranibizumab in the Treatment of Acute Central Serous Chorioretihopathy: A Single Center Retrospective Study. Semin Ophthalmol. 2018. 33 (2):265-270. [QxMD MEDLINE Link].
Kim GA, Rim TH, Lee SC, Byeon SH, Koh HJ, Kim SS, et al. Clinical characteristics of responders to intravitreal bevacizumab in central serous chorioretinopathy patients. Eye (Lond). 2015 Jun. 29 (6):732-40; quiz 741. [QxMD MEDLINE Link].
Bae SH et al. A randomized pilot study of low-fluence photodynamic therapy versus intravitrealranibizumab for chronic central serous chorioretinopathy. Am J Ophthalmol. 2011. 152:784-92.
Semeraro F, Romano MR, Danzi P, Morescalchi F, Costagliola C. Intravitreal bevacizumab versus low-fluence photodynamic therapy for treatment of chronic central serous chorioretinopathy. Jpn J Ophthalmol. 2012 Nov. 56(6):608-12. [QxMD MEDLINE Link].
Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. Am J Ophthalmol. 2007 Jun. 143(6):977-983. [QxMD MEDLINE Link].
Watzke RC, Burton TC, Woolson RF. Direct and indirect laser photocoagulation of central serous choroidopathy. Am J Ophthalmol. 1979 Nov. 88(5):914-8. [QxMD MEDLINE Link].
Robertson DM, Ilstrup D. Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy. Am J Ophthalmol. 1983 Apr. 95(4):457-66. [QxMD MEDLINE Link].
Burumcek E, Mudun A, Karacorlu S, Arslan MO. Laser photocoagulation for persistent central serous retinopathy: results of long-term follow-up. Ophthalmology. 1997 Apr. 104(4):616-22. [QxMD MEDLINE Link].
Taban M, Boyer DS, Thomas EL, Taban M. Chronic central serous chorioretinopathy: photodynamic therapy. Am J Ophthalmol. 2004 Jun. 137(6):1073-80. [QxMD MEDLINE Link].
Yannuzzi LA, Slakter JS, Gross NE, et al. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina. 2003 Jun. 23(3):288-98. [QxMD MEDLINE Link].
Reibaldi M, Boscia F, Avitabile T, et al. Functional retinal changes measured by microperimetry in standard-fluence vs low-fluence photodynamic therapy in chronic central serous chorioretinopathy. Am J Ophthalmol. 2011 Jun. 151(6):953-960.e2. [QxMD MEDLINE Link].
Bae SH, Heo JW, Kim C, et al. A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy. Am J Ophthalmol. 2011 Nov. 152(5):784-92.e2. [QxMD MEDLINE Link].
Chan WM, Lam DS, Lai TY, Tam BS, Liu DT, Chan CK. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol. 2003 Dec. 87(12):1453-8. [QxMD MEDLINE Link]. [Full Text].
Costa RA, Scapucin L, Moraes NS, et al. Indocyanine green-mediated photothrombosis as a new technique of treatment for persistent central serous chorioretinopathy. Curr Eye Res. 2002 Nov. 25(5):287-97. [QxMD MEDLINE Link].
Hussain N, Khanna R, Hussain A, Das T. Transpupillary thermotherapy for chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2006 Aug. 244(8):1045-51. [QxMD MEDLINE Link].
Shukla D, Kolluru C, Vignesh TP, Karthikprakash S, Kim R. Transpupillary thermotherapy for subfoveal leaks in central serous chorioretinopathy. Eye (Lond). 2008 Jan. 22(1):100-6. [QxMD MEDLINE Link].
Penha FM, Aggio FB, Bonomo PP. Severe retinal thermal injury after indocyanine green-mediated photothrombosis for central serous chorioretinopathy. Am J Ophthalmol. 2007 May. 143(5):887-9. [QxMD MEDLINE Link].
Gass JD, Little H. Bilateral bullous exudative retinal detachment complicating idiopathic central serous chorioretinopathy during systemic corticosteroid therapy. Ophthalmology. 1995 May. 102(5):737-47. [QxMD MEDLINE Link].
Hooymans JM. Fibrotic scar formation in central serous chorioretinopathy developed during systemic treatment with corticosteroids. Graefes Arch Clin Exp Ophthalmol. 1998 Nov. 236(11):876-9. [QxMD MEDLINE Link].
Cardillo Piccolino F, Eandi CM, Ventre L, Rigault de la Longrais RC, Grignolo FM. Photodynamic therapy for chronic central serous chorioretinopathy. Retina. 2003 Dec. 23(6):752-63. [QxMD MEDLINE Link].
Ober MD, Yannuzzi LA, Do DV, et al. Photodynamic therapy for focal retinal pigment epithelial leaks secondary to central serous chorioretinopathy. Ophthalmology. 2005 Dec. 112(12):2088-94. [QxMD MEDLINE Link].
Yannuzzi LA, Freund KB, Goldbaum M, et al. Polypoidal choroidal vasculopathy masquerading as central serous chorioretinopathy. Ophthalmology. 2000 Apr. 107(4):767-77. [QxMD MEDLINE Link].
Kim YK, Woo SJ, Park KH, Chi YK, Han JW, Kim KW. Association of Central Serous Chorioretinopathy with Psychosocial Factors is Dependent on Its Phase and Subtype. Korean J Ophthalmol. 2018 Aug. 32 (4):281-289. [QxMD MEDLINE Link].
Çiloğlu E, Unal F, Dogan NC. The relationship between the central serous chorioretinopathy, choroidal thickness, and serum hormone levels. Graefes Arch Clin Exp Ophthalmol. 2018 Jun. 256 (6):1111-1116. [QxMD MEDLINE Link].

Media Gallery

Fluorescein angiography in the early recirculation phase of a patient with a localized neurosensory detachment in the macula from central serous chorioretinopathy. Note the focal hyperfluorescence.
Fluorescein angiography in the late recirculation phase of the same patient as in the image above. Note the distribution of leakage of fluorescein dye within the neurosensory detachment.
A 45-year-old man presented with micropsia and blurry vision OS. His visual acuity was 20/15 OD and 20/30 OS. The OCT shows subretinal fluid localized under the foveal center. Six weeks later, the subretinal fluid had resolved and his vision had recovered to 20/15 OU.

of 3

Author

Kean Theng Oh, MD Consulting Staff, Associated Retinal Consultants, PC

Kean Theng Oh, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Ophthalmology, American Society of Retina Specialists, Association for Research in Vision and Ophthalmology, Michigan Society of Eye Physicians & Surgeons

Disclosure: Nothing to disclose.

Specialty Editor Board

Simon K Law, MD, PharmD Clinical Professor of Health Sciences, Department of Ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles, David Geffen School of Medicine

Simon K Law, MD, PharmD is a member of the following medical societies: American Academy of Ophthalmology, Association for Research in Vision and Ophthalmology, American Glaucoma Society

Disclosure: Nothing to disclose.

Steve Charles, MD Founder and CEO of Charles Retina Institute; Clinical Professor, Department of Ophthalmology, University of Tennessee College of Medicine

Disclosure: Received royalty and consulting fees for: Alcon Laboratories.

Chief Editor

Andrew A Dahl, MD, FACS Assistant Professor of Surgery (Ophthalmology), New York College of Medicine (NYCOM); Director of Residency Ophthalmology Training, The Institute for Family Health and Mid-Hudson Family Practice Residency Program; Staff Ophthalmologist, Telluride Medical Center

Andrew A Dahl, MD, FACS is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, American Intraocular Lens Society, American Medical Association, American Society of Cataract and Refractive Surgery, Contact Lens Association of Ophthalmologists, Medical Society of the State of New York, New York State Ophthalmological Society, Outpatient Ophthalmic Surgery Society

Disclosure: Nothing to disclose.

Additional Contributors

Brian A Phillpotts, MD Ophthalmologist, St Luke's Cataract and Laser Institute

Brian A Phillpotts, MD is a member of the following medical societies: American Academy of Ophthalmology, American Diabetes Association, American Society of Retina Specialists, Association for Research in Vision and Ophthalmology, Association of University Professors of Ophthalmology

Disclosure: Nothing to disclose.

Acknowledgements

The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous author, James C Folk, MD, to the development and writing of this article.

Sections Central Serous Chorioretinopathy
Overview
Presentation
- History
- Physical
- Causes
- Show All
DDx
Workup
Treatment
Medication
Media Gallery
References

Central Serous Chorioretinopathy Workup

Laboratory Studies

Imaging Studies

Other Tests

References

Tables

Contributor Information and Disclosures

What would you like to print?